Need professional-grade analysis? Visit stockanalysis.com
$40.12M
N/A
31
N/A
New Ray Medicine International Holding Limited (6108) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Pharmaceutical Retailers industry. The stock currently trades at HKD0.21.
Over the past year, 6108 has traded between a low of HKD0.20 and a high of HKD0.47. The stock has lost 53.9% over this period. It is currently 54.9% below its 52-week high.
New Ray Medicine International Holding Limited has a market capitalization of $40.12M.
New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People's Republic of China. The company's pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin a1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B, and chronic hepatitis C; and cefamandole nafate, ceftizoxime sodium, and isepamicin sulfate injection for the treatment of respiratory tract infections, genitourinary system infections, urinary tract infections, intra-abdominal infections, bone, joint infections, and septicemia. It also provides alanyl glutamine for injection that is indicated for catabolism and hypermetabolism; cefixime dispersible tablets to treat infections caused by streptococcus and pneumococcus, chronic bronchitis, acute bronchitis with bacterial infection, pneumonia, pyelonephritis, cystitis, gonococcal urethritis, and acute bacterial infection of the biliary tract system; and clostridium butyricum capsule for diarrhea and digestive system relevant illness. Further, the company offers marketing and promotion services. The company was founded in 2001 and is headquartered in Hangzhou, the People's Republic of China.
Side-by-side comparison against top Healthcare peers.